Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.652 USD | +6.61% | -3.07% | -58.20% |
Sales 2024 * | 14.36M 1.2B | Sales 2025 * | 27.77M 2.32B | Capitalization | 52.63M 4.39B |
---|---|---|---|---|---|
Net income 2024 * | -47M -3.92B | Net income 2025 * | -36M -3B | EV / Sales 2024 * | 3.66 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.9 x |
P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-
| Employees | 79 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRx Ltd.
1 day | +6.61% | ||
1 week | -3.07% | ||
Current month | -41.40% | ||
1 month | -23.70% | ||
3 months | -45.31% | ||
6 months | -50.65% | ||
Current year | -58.20% |
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 62 | 24/09/24 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 01/09/01 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 24/14/24 |
Avraham Molcho
BRD | Director/Board Member | 66 | 01/10/01 |
Aharon Schwartz
CHM | Chairman | 80 | 01/04/01 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 0.6563 | +7.31% | 194 817 |
26/24/26 | 0.6116 | +6.31% | 582,908 |
25/24/25 | 0.5753 | -6.15% | 636,134 |
24/24/24 | 0.613 | -3.74% | 759,134 |
23/24/23 | 0.6368 | -5.95% | 423,242 |
Delayed Quote Nasdaq, April 29, 2024 at 09:32 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.61% | 103B | |
+1.95% | 95.28B | |
+1.46% | 22.15B | |
-15.87% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.26% | 16.05B | |
+4.66% | 13.68B | |
+35.37% | 12.17B |
- Stock Market
- Equities
- BLRX Stock
- BLRX Stock